Nan Li
SelectiveNamed in filings at Dimension CapitalOn the current fund
- Board seats filed
- 6
Named in filings at Dimension CapitalOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Odyssey Therapeutics | Biotech & pharma | June 2025 | Abingworth Bioventures, Caduceus Capital, Obvious Ventures, Orbimed Genesis |
| Fiveonefour Labs | Developer tools & infrastructure | May 2025 | Obvious Ventures |
| AI Fleet | Logistics & supply chain | November 2021 | Obvious Ventures |
| ITERATIVE SCOPES | Digital health | July 2021 | Obvious Ventures |
| Hatfield | Robotics & hardware | June 2018 | Defy, Obvious Ventures |
| ZY THERAPEUTICS | Biotech & pharma | May 2016 | Obvious Ventures |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Nan Li on the board, based on 6 filed seats with a verified or cited source.